KR20220137085A - Cns 장애의 치료를 위한 세로토닌성 사이키델릭 작용제로서의 3-피롤리딘-인돌 유도체 - Google Patents

Cns 장애의 치료를 위한 세로토닌성 사이키델릭 작용제로서의 3-피롤리딘-인돌 유도체 Download PDF

Info

Publication number
KR20220137085A
KR20220137085A KR1020227030622A KR20227030622A KR20220137085A KR 20220137085 A KR20220137085 A KR 20220137085A KR 1020227030622 A KR1020227030622 A KR 1020227030622A KR 20227030622 A KR20227030622 A KR 20227030622A KR 20220137085 A KR20220137085 A KR 20220137085A
Authority
KR
South Korea
Prior art keywords
optionally substituted
atoms
available
substituted
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020227030622A
Other languages
English (en)
Korean (ko)
Inventor
압델말리크 슬라시
요셉 아라우조
Original Assignee
마인드셋 파마 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 마인드셋 파마 인크. filed Critical 마인드셋 파마 인크.
Publication of KR20220137085A publication Critical patent/KR20220137085A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/004—Acyclic, carbocyclic or heterocyclic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur, selenium or tellurium
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/572—Five-membered rings
    • C07F9/5728—Five-membered rings condensed with carbocyclic rings or carbocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G01N33/9406—Neurotransmitters
    • G01N33/942—Serotonin, i.e. 5-hydroxy-tryptamine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020227030622A 2020-02-04 2021-02-04 Cns 장애의 치료를 위한 세로토닌성 사이키델릭 작용제로서의 3-피롤리딘-인돌 유도체 Ceased KR20220137085A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062969894P 2020-02-04 2020-02-04
US62/969,894 2020-02-04
PCT/CA2021/050122 WO2021155467A1 (en) 2020-02-04 2021-02-04 3-pyrrolidine-indole derivatives as serotonergic psychedelic agents for the treatment of cns disorders

Publications (1)

Publication Number Publication Date
KR20220137085A true KR20220137085A (ko) 2022-10-11

Family

ID=77199114

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227030622A Ceased KR20220137085A (ko) 2020-02-04 2021-02-04 Cns 장애의 치료를 위한 세로토닌성 사이키델릭 작용제로서의 3-피롤리딘-인돌 유도체

Country Status (11)

Country Link
US (3) US11453689B2 (cg-RX-API-DMAC7.html)
EP (1) EP4100403A4 (cg-RX-API-DMAC7.html)
JP (2) JP7824222B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220137085A (cg-RX-API-DMAC7.html)
CN (1) CN115380028A (cg-RX-API-DMAC7.html)
AU (1) AU2021215709A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022015379A2 (cg-RX-API-DMAC7.html)
CA (1) CA3166940A1 (cg-RX-API-DMAC7.html)
IL (1) IL295374A (cg-RX-API-DMAC7.html)
MX (1) MX2022009528A (cg-RX-API-DMAC7.html)
WO (1) WO2021155467A1 (cg-RX-API-DMAC7.html)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2021215709A1 (en) * 2020-02-04 2022-09-01 Mindset Pharma Inc. 3-pyrrolidine-indole derivatives as serotonergic psychedelic agents for the treatment of CNS disorders
IL312785B2 (en) 2020-05-19 2026-06-01 Cybin Irl Ltd Deuterated tryptamine derivatives and methods of use
MX2023010317A (es) * 2021-03-02 2023-11-09 Mindset Pharma Inc Derivados del indol como agentes serotonergicos utiles para el tratamiento de trastornos relacionados con los mismos.
WO2022246572A1 (en) * 2021-05-26 2022-12-01 Mindset Pharma Inc. Hallucinogen-fatty acid combination
KR20240017363A (ko) * 2021-06-02 2024-02-07 세인트 조셉스 유니버시티 플루오린화 트립타민 화합물, 이의 유사체 및 이를 사용하는 방법
CA3229361A1 (en) * 2021-08-20 2023-02-23 Abdelmalik Slassi 3-cycloamino-indole compounds as serotonergic agents useful for the treatment of disorders related thereto
EP4452939A4 (en) * 2021-12-24 2025-12-10 Kuleon Llc SEROTONINERGIC COMPOUNDS, POLYPODS, AND PROMEDICINAL PRODIGITS OF SEROTONIN RECEPTOR AGONISTS AND ANTAGONISTS
CA3243296A1 (en) * 2022-02-01 2023-08-10 Caamtech, Inc. PSYCHEDELIC COMPOUNDS AND THEIR THERAPEUTIC USES
WO2023168023A1 (en) 2022-03-04 2023-09-07 Reset Pharmaceuticals, Inc. Co-crystals or salts comprising psilocin
JP2025513461A (ja) * 2022-04-19 2025-04-24 マインドセット ファーマ インコーポレイテッド セロトニン作動薬としてのインドリン誘導体に関連する障害の治療に有用なセロトニン作動薬としてのインドリン誘導体
CN117586171A (zh) * 2022-08-12 2024-02-23 长春金赛药业有限责任公司 吲哚类衍生物、药物组合物及其在中枢神经领域的应用
US12396981B2 (en) 2023-03-09 2025-08-26 William Shulman Methods of using DMT
WO2025104491A1 (en) 2023-11-14 2025-05-22 Mindset Pharma Inc. Indole derivatives as serotonergic agents useful for the treatment of disorders related thereto
TW202619712A (zh) * 2024-09-09 2026-05-16 大陸商翼思生物醫藥(蘇州)有限公司 5-ht2a受體激動劑及m4活化劑之組合及其用途

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5607951A (en) 1990-10-15 1997-03-04 Pfizer Inc Indole derivatives
US5559129A (en) 1990-10-15 1996-09-24 Pfizer Inc Indole derivatives
US5545644A (en) 1990-10-15 1996-08-13 Pfizer Inc. Indole derivatives
US5120749A (en) 1991-02-20 1992-06-09 Abbott Laboratories Platelet activating antagonists
TW288010B (cg-RX-API-DMAC7.html) * 1992-03-05 1996-10-11 Pfizer
AU670579B2 (en) * 1992-04-07 1996-07-25 Pfizer Inc. Indole derivatives as 5-HT1 agonists
KR960701865A (ko) * 1993-04-22 1996-03-28 데이비드 존. 우드 편두통에 사용하는 5-HT1 유사 효능제인 인돌 유도체(Indole Derivatives as 5-HT, -Like Agonists for Use in Migraine)
AP486A (en) * 1993-04-27 1996-04-16 Pfizer Indole derivatives.
FR2735774B1 (fr) 1995-06-21 1997-09-12 Sanofi Sa Utilisation de composes agonistes du recepteur cb2 humain pour la preparation de medicaments immunomodulateurs, nouveaux composes agonistes du recepteur cb2 et les compositions pharmaceutiques les contenant
JP2001503414A (ja) 1996-10-31 2001-03-13 ハーバー ブランチ オーシャノグラフィック インスティテューション インク. 抗神経性炎症化合物および組成物ならびにその使用法
US6100291A (en) 1998-03-16 2000-08-08 Allelix Biopharmaceuticals Inc. Pyrrolidine-indole compounds having 5-HT6 affinity
GB9816263D0 (en) 1998-07-24 1998-09-23 Merck Sharp & Dohme Therapeutic agents
US6218423B1 (en) 1998-08-14 2001-04-17 Gpi Nil Holdings, Inc. Pyrrolidine derivatives for vision and memory disorders
GB9923314D0 (en) 1999-10-01 1999-12-08 Pfizer Ltd Acylation process
US6841685B2 (en) 2000-06-07 2005-01-11 State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of Oregon State University Methods for making bis-heterocyclic alkaloids
US7135479B2 (en) 2002-09-12 2006-11-14 Wyeth Antidepressant azaheterocyclylmethyl derivatives of heterocycle-fused benzodioxans
WO2004106298A1 (en) 2003-05-30 2004-12-09 Janssen Pharmaceutica N.V. Indole derivatives with an improved antipsychotic activity
WO2005062985A2 (en) * 2003-12-23 2005-07-14 American Bioscience, Inc. Di-ester prodrugs of camptothecin, process for their preparation and their therapeutical applications
MX2007003375A (es) 2004-09-22 2007-05-07 Janssen Pharmaceutica Nv Inhibidores de la interaccion entre mdm2 y p53.
ATE489138T1 (de) 2005-04-13 2010-12-15 Neuraxon Inc Substituierte indolverbindungen mit nos-hemmender aktivität
US8003624B2 (en) 2005-08-25 2011-08-23 Schering Corporation Functionally selective ALPHA2C adrenoreceptor agonists
DK1981875T3 (da) 2006-01-19 2014-07-14 Janssen Pharmaceutica Nv Substituerede indolylalkylaminoderivater som inhibitorer af histondeacetylase
EP2029136A4 (en) * 2006-05-22 2010-01-06 Vanda Pharmaceuticals Inc TREATMENT FOR DEPRESSION DISEASES
US7964728B2 (en) 2006-07-06 2011-06-21 Solvay Pharmaceuticals B.V. Azaindole derivatives with a combination of partial nicotinic acetyl-choline receptor agonism and dopamine reuptake inhibition
WO2008036967A2 (en) 2006-09-22 2008-03-27 Reddy Us Therapeutics, Inc. Novel heterocyclic compounds as lasy activators
US20090014868A1 (en) 2007-07-10 2009-01-15 International Business Machines Corporation Manufacturing ic chip in portions for later combining, and related structure
EA201000808A1 (ru) 2007-11-16 2011-04-29 Ньюраксон, Инк. Индольные соединения и способы лечения висцеральной боли
US20100022581A1 (en) 2008-07-02 2010-01-28 Memory Pharmaceuticals Corporation Pyrrolidine-substituted azaindole compounds having 5-ht6 receptor affinity
WO2010132072A1 (en) 2009-05-15 2010-11-18 Neuraxon, Inc Treatment or prevention of migraine by dosing at aura
EP2668177B1 (en) 2011-01-28 2014-10-22 Boehringer Ingelheim International GmbH Substituted pyridinyl-pyrimidines and their use as medicaments
HUE039750T2 (hu) * 2014-06-26 2019-02-28 Contera Pharma Aps Hidroxi-buspiron mozgászavarok kezelésére
GB201511382D0 (en) 2015-06-29 2015-08-12 Imp Innovations Ltd Novel compounds and their use in therapy
WO2017042643A1 (en) * 2015-09-10 2017-03-16 Suven Life Sciences Limited Fluoroindole derivatives as muscarinic m1 receptor positive allosteric modulators
EP3519816A4 (en) 2016-09-29 2020-05-06 The Regents of the University of California CONNECTIONS FOR INCREASING NEURONAL PLASTICITY
WO2018094106A2 (en) 2016-11-16 2018-05-24 University Of South Florida ALLOSTERIC ANTAGONISTS OF GPRC6a AND THEIR USE IN MITIGATING PROTEINOPATHIES
CA3077053A1 (en) * 2017-09-27 2019-04-04 Ohio State Innovation Foundation Methods and compositions for inhibition of stat3
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
US12090145B2 (en) 2018-08-20 2024-09-17 Yale University Combination therapy for treating or preventing depression or other mood diseases
MX2021009037A (es) 2019-01-30 2021-10-13 Diamond Therapeutics Inc Composiciones y metodos para el manejo de trastornos.
US12616706B2 (en) 2019-03-07 2026-05-05 Arbormentis LLC Compositions and methods of use comprising substances with neural plasticity actions administered at non-psychedelic/psychotomimetic dosages and formulations
GB201907871D0 (en) 2019-06-03 2019-07-17 Small Pharma Ltd Therapeutic compositions
US20230021957A1 (en) 2019-12-04 2023-01-26 Neonmind Biosciences Inc. Use of psilocin, psilocybin or analogs thereof in weight loss, treatment of obesity and compulsive eating disorder
AU2021215709A1 (en) * 2020-02-04 2022-09-01 Mindset Pharma Inc. 3-pyrrolidine-indole derivatives as serotonergic psychedelic agents for the treatment of CNS disorders
US20210236523A1 (en) 2020-02-05 2021-08-05 Yale University Psychedelic treatment for headache disorders
IL312785B2 (en) 2020-05-19 2026-06-01 Cybin Irl Ltd Deuterated tryptamine derivatives and methods of use
WO2021116503A2 (en) 2020-06-02 2021-06-17 Small Pharma Ltd Deuterated compounds
DK4172145T3 (da) 2020-06-30 2026-07-20 Reunion Neuroscience Inc Tryptamin-prodrugs som serotonin-receptor-aktivatorer til behandling af f.eks. depression
WO2022018709A1 (en) 2020-07-21 2022-01-27 Ai Pharmaceuticals Jamaica Limited Compositions and methods for treatment of psychoses and psychotic disorders
US11000534B1 (en) 2020-10-08 2021-05-11 Lennham Pharmaceuticals, Inc. Deuterated derivatives of psilocybin and uses thereof

Also Published As

Publication number Publication date
US11453689B2 (en) 2022-09-27
JP2026053548A (ja) 2026-03-25
US20240336641A1 (en) 2024-10-10
US20230105399A1 (en) 2023-04-06
JP2023512821A (ja) 2023-03-29
BR112022015379A2 (pt) 2022-09-27
MX2022009528A (es) 2022-11-14
CA3166940A1 (en) 2021-08-12
IL295374A (en) 2022-10-01
EP4100403A4 (en) 2024-01-03
WO2021155467A1 (en) 2021-08-12
AU2021215709A1 (en) 2022-09-01
US12054504B2 (en) 2024-08-06
JP7824222B2 (ja) 2026-03-04
EP4100403A1 (en) 2022-12-14
CN115380028A (zh) 2022-11-22
US20220017550A1 (en) 2022-01-20

Similar Documents

Publication Publication Date Title
US12054504B2 (en) 3-pyrrolidine-indole derivatives as serotonergic psychedelic agents for the treatment of CNS disorders
US12054505B2 (en) Psilocin derivatives as serotonergic psychedelic agents for the treatment of CNS disorders
KR20230117597A (ko) Cns 장애의 치료를 위한 세로토닌성 작용제로서의 3-시클릭아민-인돌 유도체
US20240166630A1 (en) Indole derivatives as serotonergic agents useful for the treatment of disorders related thereto
US20250034106A1 (en) 3-cycloamino-indole compounds as serotonergic agents useful for the treatment of disorders related thereto
KR20250053094A (ko) 관련 장애의 치료에 유용한 세로토닌 작용제로서의 인돌린 유도체
HK40083776A (en) 3-pyrrolidine-indole derivatives as serotonergic psychedelic agents for the treatment of cns disorders
HK40105243A (en) Indole derivatives as serotonergic agents useful for the treatment of disorders related thereto
HK40083780A (en) Psilocin derivatives as serotonergic psychedelic agents for the treatment of cns disorders
HK40106138A (en) Indole derivatives as serotonergic agents useful for the treatment of disorders related thereto
HK40084439A (en) Psilocin derivatives as serotonergic psychedelic agents for the treatment of cns disorders

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11 Administrative time limit extension requested

Free format text: ST27 STATUS EVENT CODE: U-3-3-T10-T11-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

B15 Application refused following examination

Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B15-EXM-PE0601 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000